Autopsy report · NCT00227474
S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission
Cause of deathFunding or business
“SWOG has decided to not pursue this trial”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- SWOG Cancer Research Network
- Sponsor type
- University, hospital or other
- Conditions
- Breast Cancer
- Interventions
- recombinant modified vaccinia Ankara-5T4 vaccine; adjuvant therapy; recombinant viral vaccine therapy
- Participants
- 0
Trials that died the same way
- A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
“The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.” - Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
“Company decision to discontinue trial” - A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
“The trial prematurely terminated due to the inability to recruit the planned number of subjects. The decision to terminate the trial was not based on any safety concerns.” - Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
“Trial terminated due to business decision, not based on any safety or efficacy concerns.” - One Touch® Verio®IQ European Clinical Outcomes Study
“Business decision to withdraw trial”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.